title: [Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer].
abstract: To improve the response to chemotherapy for non-small cell lung cancer (NSCLC), effective drugs should be selected for each patient. In 1994 we introduced histoculture drug response assay (HDRA) for NSCLC patients. For clinical N2 patients, biopsy of mediastinal lymph node is performed both for histological diagnosis and for HDRA. Induction concurrent chemoradiotherapy is then performed using HDRA positive chemotherapy agents. We have treated three patients with this strategy. HDRA could be performed using mediastinal lymph node biopsy specimens. Tumor reduction rates of these patients were 80.4%, 85.3%, and 57.1%. Their histological responses were Ef.3, Ef.2, and Ef.1b, respectively. Complete resection was done in all patients. This strategy appeared to be useful in NSCLC patients with mediastinal lymph node metastasis.
authors.affiliation: Dept. of Thoracic and Cardiovascular Surgery, Wakayama Medical University.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yoshimasu
authors.forename: Shoji
authors.initials: S
authors.lastname: Oura
authors.forename: Issei
authors.initials: I
authors.lastname: Hirai
authors.forename: Yozo
authors.initials: Y
authors.lastname: Kokawa
authors.forename: Rie
authors.initials: R
authors.lastname: Sasaki
authors.forename: Kentaro
authors.initials: K
authors.lastname: Honda
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Tanino
authors.forename: Teruhisa
authors.initials: T
authors.lastname: Sakurai
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Okamura
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011013:Pneumonectomy; D043823:Taxoids; D014407:Tumor Cells, Cultured
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D005047:Etoposide; D017239:Paclitaxel; D002945:Cisplatin